Floatz logo

sm-88

Hormone Receptor Positive Breast Carcinoma

Georgetown UniversityPhase 2Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hormone Receptor Positive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Everolimus
Ellipses Pharma
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB

View all 50 →

Same molecule, other indications

sm-88 is also rated in:

malignant pancreatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
breast cancerDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →